<?xml version='1.0' encoding='utf-8'?>
<document id="26032239"><sentence text="Pharmacokinetic drug-drug interaction assessment of peptibody trebananib in combination with chemotherapies."><entity charOffset="62-72" id="DDI-PubMed.26032239.s1.e0" text="trebananib" /></sentence><sentence text="To provide the first evaluation of pharmacokinetic (PK) drug-drug interactions (DDIs) between trebananib and chemotherapies across tumor types" /><sentence text="" /><sentence text="PK data of trebananib and chemotherapies (paclitaxel, carboplatin, pegylated liposomal doxorubicin, topotecan, capecitabine, lapatinib, 5-FU, irinotecan, or docetaxel) were collected from trials of ovarian cancer, metastatic breast cancer, colorectal carcinoma, and mixed solid tumor"><entity charOffset="11-21" id="DDI-PubMed.26032239.s4.e0" text="trebananib" /><entity charOffset="42-52" id="DDI-PubMed.26032239.s4.e1" text="paclitaxel" /><entity charOffset="54-65" id="DDI-PubMed.26032239.s4.e2" text="carboplatin" /><entity charOffset="87-98" id="DDI-PubMed.26032239.s4.e3" text="doxorubicin" /><entity charOffset="100-109" id="DDI-PubMed.26032239.s4.e4" text="topotecan" /><entity charOffset="111-123" id="DDI-PubMed.26032239.s4.e5" text="capecitabine" /><entity charOffset="125-134" id="DDI-PubMed.26032239.s4.e6" text="lapatinib" /><entity charOffset="136-140" id="DDI-PubMed.26032239.s4.e7" text="5-FU" /><entity charOffset="142-152" id="DDI-PubMed.26032239.s4.e8" text="irinotecan" /><entity charOffset="157-166" id="DDI-PubMed.26032239.s4.e9" text="docetaxel" /><pair ddi="false" e1="DDI-PubMed.26032239.s4.e0" e2="DDI-PubMed.26032239.s4.e0" /><pair ddi="false" e1="DDI-PubMed.26032239.s4.e0" e2="DDI-PubMed.26032239.s4.e1" /><pair ddi="false" e1="DDI-PubMed.26032239.s4.e0" e2="DDI-PubMed.26032239.s4.e2" /><pair ddi="false" e1="DDI-PubMed.26032239.s4.e0" e2="DDI-PubMed.26032239.s4.e3" /><pair ddi="false" e1="DDI-PubMed.26032239.s4.e0" e2="DDI-PubMed.26032239.s4.e4" /><pair ddi="false" e1="DDI-PubMed.26032239.s4.e0" e2="DDI-PubMed.26032239.s4.e5" /><pair ddi="false" e1="DDI-PubMed.26032239.s4.e0" e2="DDI-PubMed.26032239.s4.e6" /><pair ddi="false" e1="DDI-PubMed.26032239.s4.e0" e2="DDI-PubMed.26032239.s4.e7" /><pair ddi="false" e1="DDI-PubMed.26032239.s4.e0" e2="DDI-PubMed.26032239.s4.e8" /><pair ddi="false" e1="DDI-PubMed.26032239.s4.e0" e2="DDI-PubMed.26032239.s4.e9" /><pair ddi="false" e1="DDI-PubMed.26032239.s4.e1" e2="DDI-PubMed.26032239.s4.e1" /><pair ddi="false" e1="DDI-PubMed.26032239.s4.e1" e2="DDI-PubMed.26032239.s4.e2" /><pair ddi="false" e1="DDI-PubMed.26032239.s4.e1" e2="DDI-PubMed.26032239.s4.e3" /><pair ddi="false" e1="DDI-PubMed.26032239.s4.e1" e2="DDI-PubMed.26032239.s4.e4" /><pair ddi="false" e1="DDI-PubMed.26032239.s4.e1" e2="DDI-PubMed.26032239.s4.e5" /><pair ddi="false" e1="DDI-PubMed.26032239.s4.e1" e2="DDI-PubMed.26032239.s4.e6" /><pair ddi="false" e1="DDI-PubMed.26032239.s4.e1" e2="DDI-PubMed.26032239.s4.e7" /><pair ddi="false" e1="DDI-PubMed.26032239.s4.e1" e2="DDI-PubMed.26032239.s4.e8" /><pair ddi="false" e1="DDI-PubMed.26032239.s4.e1" e2="DDI-PubMed.26032239.s4.e9" /><pair ddi="false" e1="DDI-PubMed.26032239.s4.e2" e2="DDI-PubMed.26032239.s4.e2" /><pair ddi="false" e1="DDI-PubMed.26032239.s4.e2" e2="DDI-PubMed.26032239.s4.e3" /><pair ddi="false" e1="DDI-PubMed.26032239.s4.e2" e2="DDI-PubMed.26032239.s4.e4" /><pair ddi="false" e1="DDI-PubMed.26032239.s4.e2" e2="DDI-PubMed.26032239.s4.e5" /><pair ddi="false" e1="DDI-PubMed.26032239.s4.e2" e2="DDI-PubMed.26032239.s4.e6" /><pair ddi="false" e1="DDI-PubMed.26032239.s4.e2" e2="DDI-PubMed.26032239.s4.e7" /><pair ddi="false" e1="DDI-PubMed.26032239.s4.e2" e2="DDI-PubMed.26032239.s4.e8" /><pair ddi="false" e1="DDI-PubMed.26032239.s4.e2" e2="DDI-PubMed.26032239.s4.e9" /><pair ddi="false" e1="DDI-PubMed.26032239.s4.e3" e2="DDI-PubMed.26032239.s4.e3" /><pair ddi="false" e1="DDI-PubMed.26032239.s4.e3" e2="DDI-PubMed.26032239.s4.e4" /><pair ddi="false" e1="DDI-PubMed.26032239.s4.e3" e2="DDI-PubMed.26032239.s4.e5" /><pair ddi="false" e1="DDI-PubMed.26032239.s4.e3" e2="DDI-PubMed.26032239.s4.e6" /><pair ddi="false" e1="DDI-PubMed.26032239.s4.e3" e2="DDI-PubMed.26032239.s4.e7" /><pair ddi="false" e1="DDI-PubMed.26032239.s4.e3" e2="DDI-PubMed.26032239.s4.e8" /><pair ddi="false" e1="DDI-PubMed.26032239.s4.e3" e2="DDI-PubMed.26032239.s4.e9" /><pair ddi="false" e1="DDI-PubMed.26032239.s4.e4" e2="DDI-PubMed.26032239.s4.e4" /><pair ddi="false" e1="DDI-PubMed.26032239.s4.e4" e2="DDI-PubMed.26032239.s4.e5" /><pair ddi="false" e1="DDI-PubMed.26032239.s4.e4" e2="DDI-PubMed.26032239.s4.e6" /><pair ddi="false" e1="DDI-PubMed.26032239.s4.e4" e2="DDI-PubMed.26032239.s4.e7" /><pair ddi="false" e1="DDI-PubMed.26032239.s4.e4" e2="DDI-PubMed.26032239.s4.e8" /><pair ddi="false" e1="DDI-PubMed.26032239.s4.e4" e2="DDI-PubMed.26032239.s4.e9" /><pair ddi="false" e1="DDI-PubMed.26032239.s4.e5" e2="DDI-PubMed.26032239.s4.e5" /><pair ddi="false" e1="DDI-PubMed.26032239.s4.e5" e2="DDI-PubMed.26032239.s4.e6" /><pair ddi="false" e1="DDI-PubMed.26032239.s4.e5" e2="DDI-PubMed.26032239.s4.e7" /><pair ddi="false" e1="DDI-PubMed.26032239.s4.e5" e2="DDI-PubMed.26032239.s4.e8" /><pair ddi="false" e1="DDI-PubMed.26032239.s4.e5" e2="DDI-PubMed.26032239.s4.e9" /><pair ddi="false" e1="DDI-PubMed.26032239.s4.e6" e2="DDI-PubMed.26032239.s4.e6" /><pair ddi="false" e1="DDI-PubMed.26032239.s4.e6" e2="DDI-PubMed.26032239.s4.e7" /><pair ddi="false" e1="DDI-PubMed.26032239.s4.e6" e2="DDI-PubMed.26032239.s4.e8" /><pair ddi="false" e1="DDI-PubMed.26032239.s4.e6" e2="DDI-PubMed.26032239.s4.e9" /><pair ddi="false" e1="DDI-PubMed.26032239.s4.e7" e2="DDI-PubMed.26032239.s4.e7" /><pair ddi="false" e1="DDI-PubMed.26032239.s4.e7" e2="DDI-PubMed.26032239.s4.e8" /><pair ddi="false" e1="DDI-PubMed.26032239.s4.e7" e2="DDI-PubMed.26032239.s4.e9" /><pair ddi="false" e1="DDI-PubMed.26032239.s4.e8" e2="DDI-PubMed.26032239.s4.e8" /><pair ddi="false" e1="DDI-PubMed.26032239.s4.e8" e2="DDI-PubMed.26032239.s4.e9" /></sentence><sentence text=" A dedicated PK DDI study of trebananib and paclitaxel in patients with mixed solid tumors was also conducted"><entity charOffset="29-39" id="DDI-PubMed.26032239.s5.e0" text="trebananib" /><entity charOffset="44-54" id="DDI-PubMed.26032239.s5.e1" text="paclitaxel" /><pair ddi="false" e1="DDI-PubMed.26032239.s5.e0" e2="DDI-PubMed.26032239.s5.e0" /><pair ddi="false" e1="DDI-PubMed.26032239.s5.e0" e2="DDI-PubMed.26032239.s5.e1" /></sentence><sentence text=" The geometric least squares mean (GLSM) ratios and corresponding 90 % confidence intervals (CI) of C max and AUC were estimated for DDI evaluations" /><sentence text="" /><sentence text="In the PK DDI study of trebananib and paclitaxel, the GLSM ratio (90 % CI) was 1"><entity charOffset="23-33" id="DDI-PubMed.26032239.s8.e0" text="trebananib" /><entity charOffset="38-48" id="DDI-PubMed.26032239.s8.e1" text="paclitaxel" /><pair ddi="false" e1="DDI-PubMed.26032239.s8.e0" e2="DDI-PubMed.26032239.s8.e0" /><pair ddi="false" e1="DDI-PubMed.26032239.s8.e0" e2="DDI-PubMed.26032239.s8.e1" /></sentence><sentence text="17 (1" /><sentence text="10-1" /><sentence text="25) for paclitaxel AUC and 1"><entity charOffset="8-18" id="DDI-PubMed.26032239.s11.e0" text="paclitaxel" /></sentence><sentence text="30 (1" /><sentence text="15-1" /><sentence text="48) for paclitaxel C max"><entity charOffset="8-20" id="DDI-PubMed.26032239.s14.e0" text="paclitaxel C" /></sentence><sentence text=" The GLSM ratio (90 % CI) for the effect of paclitaxel on trebananib PK was 0"><entity charOffset="44-54" id="DDI-PubMed.26032239.s15.e0" text="paclitaxel" /></sentence><sentence text="92 (0" /><sentence text="87-0" /><sentence text="97) for trebananib AUC and 0" /><sentence text="98 (0" /><sentence text="92-1" /><sentence text="05) for trebananib C max"><entity charOffset="8-20" id="DDI-PubMed.26032239.s21.e0" text="trebananib C" /></sentence><sentence text=" In the remaining studies, the GLSM ratios (90 % CI) of C max and AUC generally ranged from 0" /><sentence text="8 to 1" /><sentence text="25 or exhibited less than twofold PK variabilities across chemotherapeutic agents" /><sentence text=" No dose-dependent DDIs were evident" /><sentence text="" /><sentence text="No PK DDI was deemed clinically meaningful between trebananib and the tested chemotherapeutic agents to warrant dose adjustments" /><sentence text="" /></document>